Seom guidelines for the treatment of gastric cancer 2015
-
M. Martin-Richard [1] ; A. Custodio [2] ; C. García-Girón [3] ; C. Grávalos [4] ; C. Gomez [4] ; P. Jimenez-Fonseca [5] ; J. L. Manzano [6] ; C. Pericay [7] ; F. Rivera [8] ; A. Carrato [9]
-
[1] Hospital de la Santa Creu i Sant Pau
Hospital de la Santa Creu i Sant Pau
Barcelona, España
-
[2] Hospital Clínico San Carlos de Madrid
Hospital Clínico San Carlos de Madrid
Madrid, España
-
[3] Complejo Asistencial Universitario de Burgos
Complejo Asistencial Universitario de Burgos
Burgos, España
-
[4] Hospital Universitario 12 de Octubre
Hospital Universitario 12 de Octubre
Madrid, España
-
[5] Hospital Universitario Central de Asturias
Hospital Universitario Central de Asturias
Oviedo, España
-
[6] Hospital Universitari Germans Trias i Pujol
Hospital Universitari Germans Trias i Pujol
Barcelona, España
-
[7] Hospital de Sabadell
Hospital de Sabadell
Barcelona, España
-
[8] Hospital Universitario Marqués de Valdecilla
Hospital Universitario Marqués de Valdecilla
Santander, España
-
[9] Hospital Ramón y Cajal
Hospital Ramón y Cajal
Madrid, España
-
- Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 17, Nº. 12, 2015, págs. 996-1004
- Idioma: inglés
- Texto completo no disponible (Saber más ...)
-
Resumen
Gastric cancer is the fourth cause of death by cancer in Spain and a significant medical problem. Molecular biology results evidence that gastroesophageal junction tumors and gastric cancer should be considered as two independent entities with a different prognosis and treatment approach. Endoscopic resection in very early tumors is feasible. Neoadjuvant and adjuvant therapy in locally advanced resectable tumor increase overall survival and should be considered standard treatments. In stage IV tumors, platinum–fluoropyrimidine-based schedule, with trastuzumab in HER2-overexpressed tumors, is the first-line treatment. Different therapies in second line have demonstrated in randomized studies their clear benefit in survival improvement.
